Understanding Overkill Sterilization: An End to the Confusion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Understanding Overkill Sterilization: An End to the Confusion
The author clarifies the definition and objectives of overkill sterilization for steam sterilization cycles. Current sterilization practices are reviewed and the validation difficulties associated with the various definitions of overkill sterilization are explored.


Pharmaceutical Technology


The overkill method is perhaps the most common method used in the development and validation of sterilization processes. Overkill sterilization primarily is applied to the moist-heat processing of materials, supplies, and other heat-stable goods. It generally is considered to be the simplest and most straightforward method for the design and validation of moist-heat sterilization processes. Although this is true, there is substantial confusion about how to use the overkill method and, in fact, regarding what actually constitutes an overkill process. Confusion associated with the overkill approach exists in all of the widely used sterilization technologies; that is, moist heat, dry heat, gas, and radiation. This article focuses on steam sterilization, of which there is both a greater amount of published definitions and a more precise and generally accepted understanding of the underlying science.

A contemporary definition of overkill moist-heat sterilization follows: "This is usually achieved by providing a minimum 12-log reduction of microorganisms having a D-value of at least one minute at 121 °C" (1). This is a simple-enough definition. Unfortunately, it cannot be demonstrated in a straightforward manner with presently available technology. What this definition suggests is that overkill requires a 12-D process, which equates to lethality sufficient to deliver a 12 × D121 lethality level. This is not a lethality standard at all, however, because it inappropriately links the process lethality requirement to the characteristics of a specific biological indicator (BI). This article reviews present sterilization practices and explores the difficulties inherent in this definition.

Sterilization basics

Sterilization as a process can be rather simply defined as:
a validated process used to render a product free of viable organisms. In a sterilization process, the nature of microbiological death or reduction is described by an exponential function. Therefore, the number of microorganisms which survive a sterilization process can be expressed in terms of probability. While the probability may be reduced to a very low number, it can never be reduced to zero (2).


Figure 1
The difficulty lies in demonstrating the effectiveness of that process. The death of microorganisms by any sterilization method has been shown to generally follow a straight line termed the "death curve" (see Figure 1).





Figure 2
This phenomenon occurs with all microorganisms and is not restricted to any particular species. The slope of this line represents the resistance of the microorganism to the sterilization process. The death curve for organisms exhibiting substantial resistance will have a shallow slope, and those with low resistance to the sterilization process will have a much steeper slope (see Figure 2).

The difference in microbial resistance is critical to sterilization validation. The microbial genera Geobacilli, Bacilli, and Clostridia, having substantial resistance to the sterilization process, are commonly chosen as BIs to provide an appropriate evaluation of the process. These BI organisms are stipulated to be spore populations that have much higher resistance to sterilization processes than the vegetative cells that predominate in the normal microflora found in pharmaceutical production environments. Using these spores as indicator organisms creates a process challenge that is inherently worst-case. In the case of moist heat in which sterilization conditions are very well defined and understood, BIs are best used to establish that there is sufficient correlation between physically measured lethality, generally in the form of thermometric data, and biological lethality measured using calibrated BIs.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
The Effect of Carrier Material on the Measured Resistance of Spores
A Risk-Based Approach to the Use of Biological Indicators in the Development and Control of Steam-Sterilization Processes
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Understanding Overkill Sterilization: An End to the Confusion
post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
When sourcing raw materials and non-GMP intermediates or other chemicals, where are the majority of your suppliers located?
In the United States
In Western Europe
In Central and Eastern Europe
In Japan
In India
In China
In the United States
21%
In Western Europe
17%
In Central and Eastern Europe
3%
In Japan
2%
In India
27%
In China
29%
View Results
Jim MillerOutsourcing OutlookJim Miller Time for a Model Upgrade
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Navigating the Global Pharmaceutical Supply Chain
Faiz kermani SpotlightFaiz Kermani Reinvigorating European R&D innovation
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Pharma Companies and Suppliers Meet at DCAT Week
Biopharmaceutical Collaboration Is a Sign of the Times
Life After Big Pharma
PhRMA Details Its Proposal for Internet and Social-Media Standards
The Unregulated Regulator
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here